Navigation Links
Stop and go
Date:2/23/2011

Gene transcription is central to cell function, as it converts the information stored in the DNA into RNA molecules of defined sequence, which then program protein synthesis. The enzyme RNA polymerase II (Pol II) is responsible for this genetic readout, but is prone to transcriptional arrest. The biochemist Professor Patrick Cramer, Director of LMU's Genzentrum, and his research associate Dr. Alan Cheung have now shown for the first time and captured on film -- what happens when Pol II arrests at a "roadblock". They were even able to observe how transcript is reactivated. Reactivation of arrested transcriptional complexes is a normal part of the readout process, and is therefore of fundamental significance in all cells. Indeed, as Patrick Cramer points out, "It is also utilized to regulate gene activity in stem and tumor cells." (Nature online, 23 February 2011)

According to Patrick Cramer, "DNA itself is a silent molecule". It takes the enzyme RNA polymerase II to bring it to life. Pol II is the molecular machine that transcribes the genetic information encoded in the DNA into molecules of messenger RNA (mRNA). These in turn act as blueprints for the synthesis of proteins, whose structures are specified by the nucleotide sequences of the mRNAs. Since proteins, which include enzymes like Pol II, carry out most functions in cells, the process of transcription is essential for life.

Transcription is highly complex and easily perturbed. Misincorporated nucleotides and other errors are quite frequent and can cause the enzyme to arrest. In such a case, Pol II often moves in retrograde, sliding a short distance in the opposite direction along the DNA, so that the defect can be repaired. As soon as such proofreading takes place, the enzyme restarts. Sometimes, however, the enzyme moves too far backwards, and the RNA it has just synthesized gets jammed in a binding pocket.

This brings the transcription process to a complete halt, and
'/>"/>

Contact: Dr. Patrick Cramer
cramer@lmb.uni-muenchen.de
49-892-180-76965
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Researchers from the University of Illinois at Chicago have ... role in breaking down and inhibiting the formation of ... was published online this week in Nature Cell ... specialized cells are "recruited" to the wound site that ...
... and watched electrons flow through them, proving that single-molecule ... nanoscale science experiments. The finding, reported in the ... probes the effects of strong electron interactions that can ... size limit--single-molecule devices. The work resulted in the first ...
... National Eye Institute (NEI), part of the National Institutes ... translate molecular and genetic approaches from the laboratory to ... director Francis S. Collins, M.D., Ph.D., will deliver a ... feature discussions about cutting-edge treatment strategies as well as ...
Cached Biology News:Researchers discover mechanism that limits scar formation 2Stretching molecules yields new understanding of electricity 2National Eye Institute hosts Translational Research and Vision Symposium 2
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... WASHINGTON, June 15 Congressional Quarterly presents a 360-degree ... of follow-on versions of biotech drugs. This CQ Forum ... interest groups, and leading researchers regarding the complex structures ... possible? Will the availability of these products save money ...
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... of shares of convertible preferred stock pursuant to a registered ... of approximately $2 million. The preferred stock is convertible into ... investor at a price of $0.1105 per share. , ...
... Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), ... oncology, today reported that patient follow-up in the open-label ... in benign prostatic hyperplasia (BPH) with its lead endocrinology ... the end of this week. Therefore, data analysis and ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Request Info...
... is a fast and efficient ... Its high capacity and reliable design ... walk away time than typical stackers. ... set-up make for a seamless and ...
... MLF1 Interacting Protein/PBIP1 (phospho T78) ( ... Antigen: Synthetic ... 73-83 of Human MLF1 Interacting Protein ... 359815 Swiss ...
Biology Products: